Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E2LH
|
|||
| Former ID |
DIB011841
|
|||
| Drug Name |
TT-173
|
|||
| Indication | Bleeding disorder [ICD-11: GA20-GA21; ICD-10: R58] | Phase 2 | [1] | |
| Company |
Thrombotargets
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor (F3) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TWEAK Signaling Pathway | ||||
| Panther Pathway | Angiogenesis | |||
| Blood coagulation | ||||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02012569) Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting. U.S. National Institutes of Health. | |||
| REF 2 | TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.